Curative Effect of Bevacizumab Combined with Osimertinib in Advanced NSCLC with EGFRT790M Mutation
Objective To explore the clinical curative effect of bevacizumab combined with osimertinib in advanced non-small cell lung cancer(NSCLC)with epidermal growth factor receptor-T790M(EGFRT790M)mutation.Methods A total of 102 patients with advanced NSCLC and EGFRT790M mutation who were treated and pathologically confirmed were enrolled.According to random number table method,they were divided into the control group(n =51)and the observation group(n =51).The control group was treated with osimertinib,while the observation group was treated with bevacizumab combined with osimertinib for 3 months.The short-term and long-term curative effect,serum indexes[carbohydrate antigen 125(CA125),carcinoembryonic anti-gen(CEA),vascular endothelial growth factor(VEGF)]and adverse reactions during treatment were compared between the 2 groups.Results The response rate of treatment in the observation group was higher than that in the control group(56.86%vs 35.29%,P<0.05).There was no significant difference in effective control rate between the 2 groups(88.24%vs 78.43%,P>0.05).The progression rate in the observation group was lower than that of the control group(23.53%vs47.06%,P<0.05),progression-free survival was longer than that of the control group(P<0.05),and mortality was lower than that of the control group(9.80%vs 31.37%,P<0.05).After 3 months of treatment,levels of CA125,CEA and VEGF in the observation group were lower than those of the control group(P<0.05).During treatment,there was no significant difference in incidence of adverse reactions between the 2 groups(P>0.05).Conclusion The clinical curative effect of bevacizumab combined with osimertinib is good in patients with advanced NSCLC and EGFRT790M mutation,which can prolong progression-free survival and reduce expres-sion levels of tumor markers.
万方数据
维普
